Document Detail


L-threonine in the treatment of spasticity.
MedLine Citation:
PMID:  1742749     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Preclinical data indicate that the administration of the amino acid L-threonine increases glycine levels in rat spinal cord. In order to investigate glycinergic mechanisms in spasticity, and other signs of the upper motor syndrome, we gave 4.5 and 6.0 g/day of L-threonine to 18 patients with familial spastic paraparesis (FSP) according to a double-blind, crossover protocol. The response to treatment at the end of each 2-week period was based upon three measures: the physician's global impressions; the patients' global impressions; and semiquantitative ratings of strength, muscle tone, DTRs, walking, hopping, and running. Blood and CSF were collected during each treatment period for amino acid analyses. Based upon the severity rating scales, there was a statistically significant (p less than 0.02) decrease in motor impairment and spasticity during L-threonine administration compared to placebo treatment; significant treatment effects were not found on the physician's and patients' global impressions. Plasma and CSF levels of threonine increased significantly during L-threonine treatment but glycine levels did not change. These data indicate that L-threonine significantly suppressed the signs of spasticity even though the benefits were not clinically valuable.
Authors:
J H Growdon; T M Nader; J Schoenfeld; R J Wurtman
Related Documents :
22970419 - Mechanism of procedural failure related to wingspan.
18622679 - Effect of linezolid against postneurosurgical meningitis caused by methicillin-resistan...
11919449 - Choroid plexectomy reduces neurosurgical intervention in patients with hydranencephaly.
1397239 - Effectiveness of partial splenic embolization as treatment for hypersplenism in thalass...
20589639 - Juvenile xanthogranuloma with hematological dysfunction treated with 2cda-arac.
24673399 - The association between therapeutic outcomes and vegf g-1154a and c-936t gene polymorph...
17372669 - Repair of giant midline abdominal wall hernias: "components separation technique" versu...
7795149 - Long-term effects of n-3 polyunsaturated fatty acids on haemostatic variables and bleed...
17491099 - Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Clinical neuropharmacology     Volume:  14     ISSN:  0362-5664     ISO Abbreviation:  Clin Neuropharmacol     Publication Date:  1991 Oct 
Date Detail:
Created Date:  1992-01-10     Completed Date:  1992-01-10     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  7607910     Medline TA:  Clin Neuropharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  403-12     Citation Subset:  IM    
Affiliation:
Department of Neurology, Massachusetts General Hospital, Boston 02114.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Double-Blind Method
Female
Humans
Male
Middle Aged
Spastic Paraplegia, Hereditary / drug therapy*
Threonine / administration & dosage,  blood,  therapeutic use*
Grant Support
ID/Acronym/Agency:
5-M01-RR-01066/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
72-19-5/Threonine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Banisterine and Parkinson's disease.
Next Document:  Interactions of sleep and clonidine on daytime prolactin secretion in humans.